Skip to main content
EXACT Therapeutics AS logo

EXACT Therapeutics AS — Investor Relations & Filings

Ticker · EXTX ISIN · NO0010852213 LEI · 2138006ZE5JAL39AGD55 OL Manufacturing
Open in API
Filings indexed 233 across all filing types
Latest filing 2024-06-14 AGM Information
Country NO Norway
Listing OL EXTX

About EXACT Therapeutics AS

https://www.exact-tx.com/

EXACT Therapeutics AS is a clinical-stage biopharmaceutical company developing its proprietary technology platform, Acoustic Cluster Therapy (ACT®), for targeted therapeutic enhancement. The ACT® platform uses ultrasound to amplify the effect of co-administered drugs, with a primary focus on oncology. Its biomechanical mode of action increases the local uptake of therapeutics from blood vessels into the surrounding tissue, including across the blood-brain barrier, without requiring drug reformulation. This non-invasive technology is designed to be compatible with standard ultrasound systems. The company's pipeline includes the ENACT study, a Phase 2 trial evaluating ACT® in patients with locally advanced pancreatic cancer, following the completion of the ACTIVATE Phase 1 study in patients with liver metastases.

Recent filings

Filing Released Lang Actions
EXACT Therapeutics AS - Notice of Annual General Meeting 2024
AGM Information Classification · 98% confidence The document is explicitly titled 'Notice of Annual General Meeting 2024' and discusses the date, time, and location (virtual meeting) for the Annual General Meeting (AGM). It mentions that the notice includes proposed resolutions and attendance/proxy forms. This content directly relates to the preparation and announcement of the AGM. Therefore, the appropriate classification is AGM Information (AGM-R). The document length is short (1359 chars), but since it contains the core notice and agenda details rather than just announcing that a separate report is attached, AGM-R is more specific than RPA or RNS.
2024-06-14 English
Financial calendar
Report Publication Announcement Classification · 98% confidence The document text is titled 'Financial calendar' and lists key future dates for EXACT Therapeutics AS, specifically mentioning the 'Half-yearly Report' date (19.09.2024) and the 'Annual General Meeting' date (28.06.2024). This is not the report itself, nor is it the AGM presentation. It is an announcement detailing the schedule of future corporate events and reports. Since there is no specific category for a 'Financial Calendar' or 'Schedule Announcement', and it is a general regulatory disclosure ('published pursuant to the requirements set out in the Continuing obligations'), the most appropriate fallback category is Regulatory Filings (RNS).
2024-05-23 English
EXACT Therapeutics Annual report 2023
Annual Report Classification · 100% confidence The document is titled 'ANNUAL REPORT' and contains a 'Letter from the CEO', 'Board of Directors' Report', and a review of the company's operational and financial activities for the year 2023. It provides a comprehensive overview of the company's business, strategy, and performance, which aligns with the definition of an Annual Report (10-K). FY 2023
2024-04-18 English
EXACT Therapeutics Annual report 2023
Report Publication Announcement Classification · 99% confidence The document explicitly states "EXACT Therapeutics Annual report 2023" in the title and body. However, the document length is very short (2257 characters) and it primarily serves to enclose or announce the availability of the full report ("Please find enclosed the 2023 Annual Report for Exact Therapeutics."). According to Rule #2 (The 'MENU VS MEAL' Rule), a short announcement stating a report is enclosed or published should be classified as a Report Publication Announcement (RPA), rather than the full Annual Report (10-K). The content is an announcement wrapper, not the comprehensive 10-K filing itself.
2024-04-18 English
Additional promising clinical data from EXACT Therapeutics’ ongoing ACTIVATE study presented at AACR Annual Meeting
Regulatory Filings Classification · 85% confidence The document is a scientific abstract and poster presentation detailing the results of a clinical trial (NCT04021277) for 'Acoustic Cluster Therapy'. It contains medical research data, methodology, and clinical results. It does not contain financial statements, regulatory filings, or corporate governance information. As it is a scientific research document that does not fit into any of the specific financial filing categories provided, it falls under the 'Regulatory Filings' (RNS) category as the designated fallback for miscellaneous documents.
2024-04-10 English
Additional promising clinical data from EXACT Therapeutics’ ongoing ACTIVATE study presented at AACR Annual Meeting
Regulatory Filings Classification · 90% confidence The document is a press release announcing that clinical data from the ongoing ACTIVATE study was presented as a poster at the American Association for Cancer Research (AACR) Annual Meeting. It details preliminary positive results (proof of concept, safety profile) and includes commentary from the CEO. This type of announcement, focusing on research updates, clinical trial progress, and presentation of data at scientific conferences, does not fit neatly into the primary financial reporting categories (10-K, IR, ER, MRQ). It is an announcement related to the company's operations and research pipeline. Since it is not a formal financial report, a management discussion, a dividend notice, or a specific regulatory filing like DIRS or DVA, the most appropriate classification is the general 'Regulatory Filings' (RNS) category, which serves as a catch-all for significant operational announcements that aren't covered by more specific codes. Given the content is a news release about clinical data presentation, RNS is the best fit among the provided options.
2024-04-10 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.